

# MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells

TAKESHI KAWANO<sup>1\*</sup>, REHAN AHMAD<sup>\*</sup>, HIROKO NOGI<sup>1\*</sup>, NAOKI AGATA<sup>2</sup>,  
KENNETH ANDERSON and DONALD KUFE

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

Received March 31, 2008; Accepted April 29, 2008

**Abstract.** The MUC1 oncoprotein is aberrantly expressed in human multiple myeloma cells by mechanisms that are not understood. Moreover, the functional role of MUC1 in multiple myeloma is not known. The present studies demonstrate that the *MUC1* gene locus is amplified in multiple myeloma cell lines and in primary cells from patients. The KMS28PE multiple myeloma cell line, which was found to have *MUC1* gene amplification, was stably silenced for MUC1 using different siRNAs. Silencing MUC1 was associated with a decrease in nuclear  $\beta$ -catenin levels, consistent with the function of MUC1 in stabilizing  $\beta$ -catenin. MUC1 is also known to activate the IKK $\beta$ -NF- $\kappa$ B pathway and KMS28PE cells silenced for MUC1 were found to have downregulation of IKK $\beta$  and I $\kappa$ B $\alpha$  phosphorylation, and decreased nuclear targeting of NF- $\kappa$ B p65. The results also demonstrate that MUC1: i) contributes to KMS28PE cell proliferation, and ii) protects against apoptosis and loss of self-renewal in the response to melphalan and dexamethasone. These findings indicate that MUC1 activates the  $\beta$ -catenin and NF- $\kappa$ B pathways in multiple myeloma cells and contributes to their growth and survival.

## Introduction

The canonical Wnt pathway regulates cytoplasmic levels of  $\beta$ -catenin and is of importance to tumorigenesis (1). Glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) in a complex with the adenomatous polyposis coli (APC) protein and axin targets  $\beta$ -catenin

for ubiquitination and degradation. Downregulation of GSK3 $\beta$  by Wnt signaling increases levels of  $\beta$ -catenin, promotes the formation of  $\beta$ -catenin complexes with the Tcf/Lef family of transcription factors and thereby activates Wnt target genes (2,3). The Wnt pathway is constitutively activated in human multiple myeloma cells by an unclear mechanism that does not appear to involve: i) loss of APC or axin function, or ii) activating  $\beta$ -catenin mutations (4,5). Aberrant expression of  $\beta$ -catenin in multiple myeloma as compared to normal progenitor cells is associated with increased proliferation (4). Moreover, disruption of the  $\beta$ -catenin/Tcf transcription complex reduces growth and survival of multiple myeloma cells (6). These findings and those obtained with agents that disrupt  $\beta$ -catenin/Tcf-mediated transcription (7,8) have indicated that the Wnt/ $\beta$ -catenin pathway is of importance to the pathogenesis of multiple myeloma.

The classical nuclear factor- $\kappa$ B (NF- $\kappa$ B) pathway is also constitutively activated in multiple myeloma cells by mechanisms that are not clearly understood (9,10). NF- $\kappa$ B p65 is sequestered in the cytosol by binding to I $\kappa$ B $\alpha$  (11,12). The I $\kappa$ B kinase  $\beta$  (IKK $\beta$ ) in a complex with IKK $\gamma$  is necessary and sufficient for phosphorylation and thereby degradation of I $\kappa$ B $\alpha$ . In turn, NF- $\kappa$ B p65 is released for nuclear targeting and activation of NF- $\kappa$ B-dependent genes. Importantly, inhibition of constitutive NF- $\kappa$ B activation in multiple myeloma cells with agents that block IKK $\beta$  is associated with loss of proliferation and death (13-16). These findings have indicated that, as found for the Wnt/ $\beta$ -catenin pathway, the multiple myeloma cell phenotype is dependent on NF- $\kappa$ B signaling.

The MUC1 heterodimeric transmembrane protein is aberrantly expressed by human multiple myeloma cells (17-23). The extracellular MUC1 N-terminal subunit (MUC1-N) contains variable numbers of 20 amino acid tandem repeats that are modified by O-glycosylation (24,25). The transmembrane MUC1 C-terminal subunit (MUC1-C) consists of a 58 amino acid extracellular region and a 72 amino acid cytoplasmic tail (26). MUC1-C accumulates in the cytoplasm of multiple myeloma cells and is targeted to the nucleus (27). Studies in multiple myeloma and other cell types have demonstrated that the MUC1 cytoplasmic domain (MUC1-CD) binds to  $\beta$ -catenin (27-29) and stabilizes  $\beta$ -catenin by blocking function of the destruction complex (30). Recent work has further shown that MUC1-C plays a role in constitutive activation of the IKK $\beta$ -NF- $\kappa$ B p65 pathway (31). In addition, other studies

---

*Correspondence to:* Dr Donald Kufe, Dana-Farber Cancer Institute, Boston, MA 02115, USA

E-mail: donald\_kufe@dfci.harvard.edu

*Present addresses:* <sup>1</sup>Jikei University School of Medicine, Tokyo, Japan; <sup>2</sup>Pfizer Japan, Inc., Tokyo, Japan

\*Contributed equally

**Key words:** MUC1, multiple myeloma,  $\beta$ -catenin, NF- $\kappa$ B, growth, self-renewal

Table I. The primers used in this study.

Gene	Forward primers	Reverse primers	Fragments	TaqMan probe or SYBR Green
MUC1	5'-GCCAGGATCTGTGGTGG TACA-3'	5'-CTCCAGGTCGTGGAC ATTGA-3'	70-bp	6FAM-TTGACTCTGGCCTTCC CGAGAAGGTACC-3'TAMRA
TRIM46	5'-CACTGGACAAATCATTC AACAACTT-3'	5'-AAACATTATCTCACA CCATCCTCTCA-3'	127-bp	6FAM-TGCCCTGCAATGTCC ATACCTAAAGGGT-3'TAMRA
THBS3	5'-GCTTAAATAGTGACCAC CGGGT-3'	5'-AACGCTGCTCATGGA AGCC-3'	65-bp	SYBR Green
GAPDH	5'-GGTTTACATGTTCCAAT ATGATTCCA-3'	5'-ATGGGATTTCATTG ATGACAAG-3'	93-bp	6FAM-ATGGCACCGTCAAGG CTGAGAACG-3'TAMRA

have demonstrated that MUC1 induces transformation (30,32). However, it is not known whether MUC1 has similar functions in multiple myeloma cells.

The present studies demonstrate that the *MUC1* locus is amplified in multiple myeloma cell lines and primary cells. The results also demonstrate that overexpression of MUC1 contributes to: i) constitutive activation of the  $\beta$ -catenin and NF- $\kappa$ B pathways, and ii) growth and survival of multiple myeloma cells.

## Materials and methods

**Cell culture.** Human multiple myeloma cell lines were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Mediatech, Herndon, VA), 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin and 2 mM L-glutamine (ATCC, Manasses, VA). Cells were treated with melphalan and dexamethasone (Sigma, St. Louis, MO).

**Primary multiple myeloma cells.** Bone marrow mononuclear cells from patients with multiple myeloma were CD138-enriched using anti-CD138 magnetic microbeads (Miltenyi Biotec, Auburn, CA). The resulting populations were >95% CD138<sup>+</sup> cells.

**Quantitative real-time PCR.** Quantification of *MUC1*, *TRIM46*, *THBS3* and *GAPDH* gene copy number was performed on genomic DNA using primer pairs with TaqMan probes or SYBR Green (Table I) and the ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA). Relative gene copy number was determined using the comparative Ct method with GAPDH as the internal control.

**Immunoblot analysis.** Whole cell lysates (WCL), and nuclear and cytoplasmic fractions were prepared as previously described (30,31,33). Soluble proteins were subjected to immunoblot analysis with anti-MUC1-C (LabVision, Fremont, CA), anti- $\beta$ -actin (Sigma), anti- $\beta$ -catenin (BD Biosciences, San Jose, CA), anti-lamin B (Calbiochem, San Diego, CA), anti-I $\kappa$ B $\alpha$ , anti-NF- $\kappa$ B p65 (Santa Cruz Biotechnology, Santa

Cruz, CA), anti-phospho-I $\kappa$ B $\alpha$ , anti-phospho-IKK $\beta$ , anti-IKK $\beta$  (Cell Signaling Technology, Danvers, MA). Reactivity was detected with horseradish peroxidase-conjugated second antibodies and chemiluminescence (ECL Plus; GE Healthcare Biosciences, Piscataway, NJ).

**Silencing of *MUC1* expression.** The BLOCK-iT Target Screening System (Invitrogen, Carlsbad, CA) was used to generate siRNAs that target two different MUC1 sequences (#1: AAGGTACCATCAATGTCCACG; and #2: AAGTTCAGTGCCAGCTCTAC) or a control sequence (CR: CGCTTACCGATTTCAGAAATGG). The siRNA cassettes were transferred to pLenti4/BLOCK-iT-DEST by LR recombination for generation of lentiviral vectors. Cells were infected with the lentiviruses at a multiplicity of infection of 5 in the presence of 8  $\mu$ g/ml polybrene. Cell clones were selected in methylcellulose semi-solid medium containing 200  $\mu$ g/ml zeocin and assayed for downregulation of MUC1 by immunoblotting.

**Apoptosis assays.** Cells were fixed with 70% ethanol and incubated in PBS containing 20 ng/ml RNase (Roche, Indianapolis, IN) for 60 min at 37°C. Cells were then stained with 2.5  $\mu$ g/ml propidium iodide for 30 min at room temperature in the dark. DNA content was then analyzed by flow cytometry. The percentage of cells with sub-G1 DNA was determined by the Modfit LT Program (Verity Software, Topsham, ME).

**Colony formation assays.** Cells were seeded at 5,000 per well of a 6-well plate containing 0.4% methylcellulose in RPMI-1640 medium supplemented with 10% heat-inactivated FBS. Colonies were counted at 28 days under a stereomicroscope.

## Results and Discussion

**Amplification of the *MUC1* locus in multiple myeloma cells.** MUC1 is detectable in multiple myeloma cell lines and primary cells from patients, but not in CD34<sup>+</sup> hematopoietic progenitor cells (17-23). Little, however, is known about the mechanisms responsible for MUC1 expression in multiple

Table II. *MUC1* gene copy number in cell lines and primary cells.

Cell lines		Primary cells	
Multiple myeloma cell line	<i>MUC1</i> copy no.	Multiple myeloma Bone marrow	<i>MUC1</i> copy no.
U266	1	1	4
RPMI-8226	1	2	6
INA6	1	3	2
KMS-38	1	4	3
KMS-12-PE	1	5	3
KMS-12-BM	1	6	14
OCIMY-5	1	7	4
L363	2	8	3
Korpas 620	2	9	1
KMM-1	2	10	2
ARK	2	11	3
S6B45	3	12	3
MM1.S	3	13	3
SK-MM-1	3	14	4
H11112	3	15	2
LP1	3	16	3
OCIMY-7	3	17	3
KMS-18	3	18	3
XG1	3	19	2
KMS28PE	4	20	2
NCIH929	5	21	2

*MUC1* gene copy number per haploid genome was determined using *GAPDH* as the internal control.

myeloma cells. Although subsets of B cell lymphomas have amplification of the *MUC1* gene (34), there are no reports of alterations of the *MUC1* locus in multiple myeloma cells. *MUC1* gene copy number in multiple myeloma cells was assessed by quantitative real-time PCR amplification of a 70-bp fragment located outside the tandem repeat region. *GAPDH* was used as a reference gene with amplification of a 93-bp fragment. Copy number ratios for *MUC1* as compared to *GAPDH* were determined for 21 multiple myeloma cell lines (Table II). Eleven of the multiple myeloma cell lines had  $\leq 2$  and were scored as not having significant amplification of the *MUC1* locus (Table II). By contrast, 10 multiple myeloma cell lines had ratios ranging from 3 to 5 (Table II). Thus, 48% of the multiple myeloma cell lines exhibited a  $>2$ -fold increase in *MUC1* copy number. Amplification of *MUC1* as found in NCIH929 and KMS28PE cells was associated with an increase in MUC1-C expression as compared to that in U266 and RPMI8226 cells with a single *MUC1* copy number (Fig. 1A). The *MUC1* locus is flanked by the *TRIM46* and *THBS3* genes (Fig. 1B). To determine if increases in *MUC1* copy number are associated with amplification of this region, we studied *TRIM46* and *THBS3*




Figure 1. Amplification of the *MUC1* locus in multiple myeloma cells. A, Whole cell lysates from the indicated multiple myeloma cell lines were immunoblotted with anti-MUC1-C and anti- $\beta$ -actin. B, Location of the *TRIM46*, *MUC1* and *THBS3* genes in chromosome 1. C, Copy number for *TRIM46* (open bars), *MUC1* (shaded bars) and *THBS3* (solid bars) in the KMS28PE and NCIH929 cell lines and primary multiple myeloma cells.

in NCIH929 and KMS28PE cells. The results show that amplification of *MUC1* is associated with increases in *TRIM46* copy number and, to a lesser extent, *THBS3*, indicating that the regions flanking *MUC1* are also subject to amplification (Fig. 1C). Amplification of the *MUC1* locus ( $>2$ -fold) was also identified in 14 of 21 (66%) samples obtained from multiple myeloma patients (Table II) and was associated with varying increases in *TRIM46* and *THBS3* gene copy number (Fig. 1C). These findings indicate that aberrant expression of *MUC1* in multiple myeloma cells can be attributed, at least in part, to amplification of the *MUC1* locus.

*Silencing MUC1 in KMS28PE cells attenuates activation of the  $\beta$ -catenin pathway and decreases cell growth.* To assess the functional contribution of *MUC1* amplification and over-expression to the multiple myeloma cell phenotype, we infected the KMS28PE cells with a lentivirus expressing a siRNA that targets the *MUC1* sequence 5'-AAGGTACCATC AATGTCCACG-3' (*MUC1*siRNA#1) in MUC1-C. Compared to KMS28PE cells infected with a lentivirus expressing a control siRNA (CsiRNA), *MUC1*-C levels were down-regulated by *MUC1*siRNA#1 (Fig. 2A). To avoid potential off-target effects, we also infected KMS28PE cells with a lentivirus expressing a siRNA that targets a different *MUC1* sequence (5'-AAGTTCAGTGCCAGCTCTAC-3';




Figure 2. Effects of silencing MUC1 on proliferation of KMS28PE cells. A, Lysates from KMS28PE cells stably infected with lentiviruses expressing the control siRNA (A and B clones), MUC1siRNA#1 or MUC1siRNA#2 were immunoblotted with anti-MUC1-C and anti-β-actin. B, Nuclear lysates from the indicated KMS28PE cells were immunoblotted with anti-β-catenin and, as controls for loading and purity, with antibodies against nuclear lamin B and cytosolic IκBα. Whole cell lysate (WCL) was used as a control for IκBα. C and D, Proliferation of the KMS28PE cell clones CsRNA-A (solid circles), CsRNA-B (solid squares), MUC1siRNA#1 (open circles) and MUC1siRNA#2 (open squares) in 10% (C) and 2% (D) FBS.

MUC1siRNA#2) in MUC1-N. Downregulation of MUC1-C was similar with the two MUC1siRNAs (Fig. 2A), consistent with a single MUC1 transcript encoding both MUC1-N and MUC1-C. The MUC1-C subunit stabilizes β-catenin and contributes to activation of the Wnt pathway (28-30). In concert with this function, silencing MUC1-C in KMS28PE cells was associated with downregulation of nuclear β-catenin levels (Fig. 2B). Silencing MUC1 had no apparent effect on growth of KMS28PE cells in 10% FBS (Fig. 2C). However, proliferation of the KMS28PE/MUC1siRNA cells was significantly decreased in the presence of 2% FBS (Fig. 2D). These findings indicate that silencing MUC1-C is associated with decreased: i) activation of β-catenin and: ii) growth in the presence of low serum.

**Silencing MUC1 in multiple myeloma cells attenuates NF-κB activation.** Recent work has demonstrated that MUC1-C binds directly to IKKβ and confers constitutive activation of the NF-κB pathway in carcinoma cells (31). The NF-κB pathway is also activated in multiple myeloma cells (13-15,35). Consistent with these findings, NF-κB p65 was detectable in nuclear lysates of KMS28PE cells (Fig. 3A). Notably, however, silencing MUC1 decreased nuclear levels of NF-κB p65 (Fig. 3A). The results also demonstrate that silencing MUC1

decreases phospho-IKKβ levels (Fig. 3B), supporting a role for MUC1 in IKKβ activation. Moreover, phosphorylation of IκBα was decreased in KMS28PE cells silenced for MUC1 (Fig. 3C). These findings indicate that, as found in carcinoma cells (31), MUC1 contributes to activation of the IKKβ-NF-κB pathway in KMS28PE cells.

**Silencing MUC1 sensitizes KMS28PE cells to melphalan and dexamethasone.** To determine if silencing MUC1 affects death drug-induced apoptosis, KMS28PE/CsRNA and KMS28PE/MUC1siRNA cells were treated with melphalan and then monitored for sub-G1 DNA content. In concert with the effects of MUC1-C on NF-κB activation, the results show that silencing MUC1 sensitizes cells to melphalan-induced apoptosis (Fig. 4A). Silencing MUC1 also increased the apoptotic response of KMS28PE cells to dexamethasone (Fig. 4A). These results were confirmed in repetitive experiments with cells expressing MUC1siRNA#1 and MUC1siRNA#2 (Fig. 4B). To further assess the effects of silencing MUC1, the KMS28PE cells were treated with melphalan and then assayed for colony formation. The results demonstrate that silencing MUC1 increases melphalan-induced loss of self-renewal (Fig. 4C). Dexamethasone-induced decreases in self-renewal were also potentiated by






Figure 3. Constitutive activation of the IKK $\beta$ -NF- $\kappa$ B pathway in KMS28PE cells is attenuated by silencing MUC1. A, Nuclear fractions from the indicated cells were immunoblotted with anti-NF- $\kappa$ B p65 and antibodies against nuclear lamin B and cytosolic I $\kappa$ B $\alpha$ . B, Whole cell lysates were immunoblotted with anti-phospho-IKK $\beta$  and anti-IKK $\beta$ . C, Cytosolic fractions were blotted with anti-phospho-I $\kappa$ B $\alpha$  and anti-I $\kappa$ B $\alpha$ .




Figure 4. Silencing MUC1 sensitizes to melphalan- and dexamethasone-induced death. A, The indicated KMS28PE cells were treated with 4  $\mu$ M melphalan or 50  $\mu$ M dexamethasone for 72 h, stained with propidium iodide and assayed for sub-G1 DNA content by flow cytometry. The percentage of cells with sub-G1 DNA is indicated in each panel. B, The percentage of apoptotic cells with sub-G1 DNA is expressed as the mean  $\pm$  SD obtained from three experiments for the indicated control (open bars), melphalan-treated (solid-bars) and dexamethasone-treated (shaded bars) cells. C, The indicated KMS28PE cells were treated with 4  $\mu$ M melphalan or 50  $\mu$ M dexamethasone for 24 h and then seeded in 0.4% methycellulose/RPMI-1640 medium with 10% FBS. Colonies were counted at 28 days. The results are expressed as the colony number (mean  $\pm$  SD for three experiments).

silencing MUC1 (Fig. 4C). These findings thus demonstrate that MUC1 blocks induction of apoptosis and protects against loss of self-renewal capacity in the response to melphalan and dexamethasone.

**Role of MUC1 expression in multiple myeloma cells.** MUC1-C interacts with diverse signaling molecules that include growth factor receptors (36,37), kinases (c-Src, c-Abl, Bcr, Lyn, PKC $\delta$ , IKK $\beta$ ) (27,38-41) and transcription factors ( $\beta$ -catenin, p53) (30,42). The available evidence indicates that MUC1-C functions as a chaperone that holds client proteins in certain configurations that affect stability or activity (30,42,43). In multiple myeloma cells, constitutive activation of the Wnt/ $\beta$ -catenin and NF- $\kappa$ B pathways has been identified as being of importance to the malignant phenotype. The present results demonstrate that expression of MUC1 in multiple myeloma cells contributes to nuclear targeting of  $\beta$ -catenin. MUC1 expression was also associated with activation of IKK $\beta$ , phosphorylation of I $\kappa$ B $\alpha$  and targeting of NF- $\kappa$ B p65 to the nucleus. Notably, recent work has demonstrated that mutations in the NF- $\kappa$ B pathway are frequently associated with its constitutive activation in multiple myeloma cells (16,44). Thus, further studies will be needed to assess involvement of MUC1 in multiple myeloma cells with activating mutations of the NF- $\kappa$ B pathway. In concert with findings that blocking the Wnt/ $\beta$ -catenin (4,6-8) or NF- $\kappa$ B (13-16) pathways affects growth and survival of multiple myeloma cells, our results using KMS28PE cells indicate that silencing MUC1 has similar effects. In this context, MUC1 expression was associated with increased proliferation in low serum concentrations, indicating that MUC1 can protect against growth factor deprivation. Moreover, MUC1 protected against the induction of cell death in response to melphalan and dexamethasone. These findings thus indicate that MUC1 activates the  $\beta$ -catenin and NF- $\kappa$ B pathways in multiple myeloma cells and contributes to their growth and survival.

## Acknowledgements

This work was supported by the National Cancer Institute Grant CA100707.

## References

- Polakis P: Wnt signaling and cancer. *Genes Dev* 14: 1837-1851, 2000.
- Korinek V, Barker N, Morin PJ, *et al*: Constitutive transcriptional activation by a  $\beta$ -catenin-Tcf complex in APC<sup>-/-</sup> colon carcinoma. *Science* 275: 1784-1787, 1997.
- Morin PJ, Sparks AB, Korinek V, *et al*: Activation of  $\beta$ -catenin-Tcf signaling in colon cancer by mutations in  $\beta$ -catenin or APC. *Science* 275: 1787-1790, 1997.
- Derksen PW, Tjin E, Meijer HP, *et al*: Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. *Proc Natl Acad Sci USA* 101: 6122-6127, 2004.
- Qiang YW, Endo Y, Rubin JS and Rudikoff S: Wnt signaling in B-cell neoplasia. *Oncogene* 22: 1536-1545, 2003.
- Sukhdeo K, Mani M, Zhang Y, *et al*: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. *Proc Natl Acad Sci USA* 104: 7516-7521, 2007.
- Yasui H, Hideshima T, Hamasaki M, *et al*: SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. *Blood* 106: 706-712, 2005.
- Yasui H, Hideshima T, Ikeda H, *et al*: Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway. *Leukemia* 21: 535-540, 2007.
- Chauhan D, Uchiyama H, Akbarali Y, *et al*: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. *Blood* 87: 1104-1112, 1996.
- Hideshima T, Chauhan D, Schlossman R, Richardson P and Anderson KC: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. *Oncogene* 20: 4519-4527, 2001.
- Yamamoto Y and Gaynor R: I $\kappa$ B kinases: key regulators of the NF- $\kappa$ B pathway. *Trends Biochem Sci* 29: 72-79, 2003.
- Hayden MS and Ghosh S: Signaling to NF-kappaB. *Genes Dev* 18: 2195-2224, 2004.
- Hideshima T, Chauhan D, Richardson P, *et al*: NF-kappa B as a therapeutic target in multiple myeloma. *J Biol Chem* 277: 16639-16647, 2002.
- Hideshima T, Neri P, Tassone P, *et al*: MLN120B, a novel I $\kappa$ B kinase beta inhibitor, blocks multiple myeloma cell growth *in vitro* and *in vivo*. *Clin Cancer Res* 12: 5887-5894, 2006.
- Jourdan M, Moreaux J, Vos JD, *et al*: Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. *Br J Haematol* 138: 160-168, 2007.
- Annunziata CM, Davis RE, Demchenko Y, *et al*: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell* 12: 115-130, 2007.
- Takahashi T, Makiguchi Y, Hinoda Y, *et al*: Expression of MUC-1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. *J Immunol* 153: 2102-2109, 1994.
- Treon SP, Mollick JA, Urashima M, *et al*: Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. *Blood* 93: 1287-1298, 1999.
- Burton J, Mishina D, Cardillo T, *et al*: Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. *Clin Cancer Res* 5: S3065-S3072, 1999.
- Paydas S, Sahin B, Gonlusen G, Hazar B and Zorludemir S: MUC1 expression in plasmacytoma. *Leuk Res* 25: 221-225, 2001.
- Choi C, Witzens M, Bucur M, *et al*: Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. *Blood* 105: 2132-2134, 2005.
- Cloosen S, Gratama J, van Leeuwen EB, *et al*: Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. *Br J Haematol* 135: 513-516, 2006.
- Baldus SE, Palmen C and Thiele J: MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. *Histol Histopathol* 22: 889-893, 2007.
- Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell JA: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. *J Biol Chem* 263: 12820-12823, 1988.
- Siddiqui J, Abe M, Hayes D, Shani E, Yunis E and Kufe D: Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. *Proc Natl Acad Sci USA* 85: 2320-2323, 1988.
- Merlo G, Siddiqui J, Cropp C, *et al*: DF3 tumor-associated antigen gene is located in a region on chromosome 1q frequently altered in primary human breast cancer. *Cancer Res* 49: 6966-6971, 1989.
- Li Y, Chen W, Ren J, *et al*: DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. *Cancer Biol Ther* 2: 187-193, 2003.
- Yamamoto M, Bharti A, Li Y and Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and  $\beta$ -catenin in cell adhesion. *J Biol Chem* 272: 12492-12494, 1997.
- Li Y, Bharti A, Chen D, Gong J and Kufe D: Interaction of glycogen synthase kinase 3 $\beta$  with the DF3/MUC1 carcinoma-associated antigen and  $\beta$ -catenin. *Mol Cell Biol* 18: 7216-7224, 1998.
- Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D: MUC1 oncoprotein blocks GSK3 $\beta$ -mediated phosphorylation and degradation of  $\beta$ -catenin. *Cancer Res* 65: 10413-10422, 2005.

31. Ahmad R, Raina D, Trivedi V, *et al*: MUC1 oncoprotein activates the I $\kappa$ B kinase  $\beta$  complex and constitutive NF- $\kappa$ B signaling. *Nat Cell Biol* 9: 1419-1427, 2007.
32. Li Y, Liu D, Chen D, Kharbanda S and Kufe D: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. *Oncogene* 22: 6107-6110, 2003.
33. Ren J, Agata N, Chen D, *et al*: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. *Cancer Cell* 5: 163-175, 2004.
34. Dyomin VG, Palanisamy N, Lloyd KO, *et al*: MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. *Blood* 95: 2666-2671, 2000.
35. Ni H, Ergin M, Huang Q, *et al*: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. *Br J Haematol* 115: 279-286, 2001.
36. Li Y, Ren J, Yu W-H, *et al*: The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and  $\beta$ -catenin. *J Biol Chem* 276: 35239-35242, 2001.
37. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S and Kufe D: The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. *Mol Cell* 27: 992-1004, 2007.
38. Li Y, Kuwahara H, Ren J, Wen G and Kufe D: The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 $\beta$  and  $\beta$ -catenin. *J Biol Chem* 276: 6061-6064, 2001.
39. Raina D, Ahmad R, Kumar S, *et al*: MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. *EMBO J* 25: 3774-3783, 2006.
40. Ren J, Li Y and Kufe D: Protein kinase C  $\delta$  regulates function of the DF3/MUC1 carcinoma antigen in  $\beta$ -catenin signaling. *J Biol Chem* 277: 17616-17622, 2002.
41. Kawano T, Ito M, Wu Z, *et al*: MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. *Cancer Res* 67: 11576-11584, 2007.
42. Wei X, Xu H and Kufe D: Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. *Cancer Cell* 7: 167-178, 2005.
43. Wei X, Xu H and Kufe D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. *Mol Cell* 21: 295-305, 2006.
44. Keats JJ, Fonseca R, Chesi M, *et al*: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell* 12: 131-144, 2007.